Evan Kearns Biography and Net Worth

Insider of Cogent Biosciences

Evan joined Cogent in May 2021 and is responsible for the company’s legal and compliance functions. Evan is a team-oriented leader with more than a dozen years of experience serving as both in-house and outside counsel to biotech companies. Prior to joining Cogent, Evan served as Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer at Agenus Inc. (NASDAQ: AGEN), where he advised on corporate and securities law matters, as well as M&A, financing and licensing transactions. Before joining Agenus, Evan spent several years as a life sciences corporate associate with Goodwin Proctor LLP in Boston. Evan earned his JD from the University of Toledo College of Law and his BA in Economics from Colby College. In his spare time, Evan is usually in an ice rink or on a ball field or golf course with his wife and three children.

What is Evan Kearns' net worth?: The estimated net worth of Evan Kearns is at least $4.16 million as of December 26th, 2025. Kearns owns 109,398 shares of Cogent Biosciences stock worth more than $4,161,062 as of January 14th. This net worth evaluation does not reflect any other assets that Kearns may own. Learn More about Evan Kearns' net worth.
How old is Evan Kearns?: Kearns is currently 44 years old. There are 3 older executives and no younger executives at Cogent Biosciences. The oldest executive at Cogent Biosciences is Dr. John Edward Robinson Ph.D., Chief Scientific Officer, who is 49 years old. Learn More on Evan Kearns' age.
How do I contact Evan Kearns?: The corporate mailing address for Kearns and other Cogent Biosciences executives is 2650 NORTH MILITARY TRAIL SUITE 300, BOCA RATON FL, 33431. Cogent Biosciences can also be reached via phone at (617) 945-5576 and via email at [email protected]. Learn More on Evan Kearns' contact information.
Has Evan Kearns been buying or selling shares of Cogent Biosciences?: Evan Kearns has not been actively trading shares of Cogent Biosciences during the last ninety days. Most recently, Evan Kearns sold 65,000 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $38.70, for a transaction totalling $2,515,500.00. Following the completion of the sale, the insider now directly owns 109,398 shares of the company's stock, valued at $4,233,702.60. Learn More on Evan Kearns' trading history.
Who are Cogent Biosciences' active insiders?: Cogent Biosciences' insider roster includes John Green (CFO), Evan Kearns (Insider), and Jessica Sachs (Insider). Learn More on Cogent Biosciences' active insiders.
Are insiders buying or selling shares of Cogent Biosciences?: In the last twelve months, Cogent Biosciences insiders bought shares 1 times. They purchased a total of 2,777,777 shares worth more than $24,999,993.00. In the last twelve months, insiders at the technology company sold shares 3 times. They sold a total of 237,642 shares worth more than $9,200,345.40. The most recent insider tranaction occured on December, 26th when insider Evan Kearns sold 65,000 shares worth more than $2,515,500.00. Insiders at Cogent Biosciences own 7.3% of the company. Learn More about insider trades at Cogent Biosciences.
Information on this page was last updated on 12/26/2025.

Evan Kearns Insider Trading History at Cogent Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/26/2025	Sell	65,000	$38.70	$2,515,500.00	109,398

Evan Kearns Buying and Selling Activity at Cogent Biosciences

Cogent Biosciences Company Overview

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $38.22

$35.09

$38.35

50 Day Range

MA: $36.08

$14.42

$42.11

2 Week Range

Now: $38.22

$3.72

$43.73

Volume

882,102 shs

Average Volume

2,274,121 shs

Market Capitalization

$5.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Evan Kearns Biography and Net Worth

What is Evan Kearns' net worth?

How old is Evan Kearns?

How do I contact Evan Kearns?

Has Evan Kearns been buying or selling shares of Cogent Biosciences?

Who are Cogent Biosciences' active insiders?

Are insiders buying or selling shares of Cogent Biosciences?